Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- products for treating diabetes and obesity (84.3%);
- hemophilia treatment products (8.4%): mainly injections of protein;
- growth hormones (6%): used for treatment of growth deficiencies in children;
- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.
Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).